- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03179228
Prostate Artery Embolization for the Treatment of Benign Prostatic Hyperplasia
Phase II, Single Arm Prospective Study To Evaluate Safety And Efficacy Of Prostate Artery Embolization In Patients With Lower Urinary Tract Symptoms Due To Benign Prostatic Hyperplasia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a phase II, single center, prospective, single arm, investigational study to evaluate the safety and efficacy of prostate artery embolization (PAE) for treatment of severe lower urinary tract symptoms (LUTS) related to BPH in patients with prostate size greater than 40 grams that either refuse surgical treatment or are considered poor candidates for traditional surgical therapy. Two hundred patients will be enrolled in the single treatment arm with follow-up for no less than 12 months.
The study will involve a screening period in which patient eligibility will be determined. Once eligibility is confirmed, patients will receive PAE with bland microspheres within 4 weeks of screening baseline imaging. After treatment, patients will return for follow-up visits at 1 month, 3 months, 6 months, and 12 months post PAE. At each of these visits, patients will complete IPSS and IIEF questionnaires, undergo a physical exam, laboratory assessment (including PSA) and perform a medication review. Repeat TRUS and uroflowmetry will be performed at the 3, 6, and 12 month post PAE follow-up visits. MRI or CT will be conducted at the 3 and 12 month visit. Cystoscopy and proctoscopy will be performed if medically indicated.
The primary endpoint will be improvement of BPH symptoms as assessed by the IPSS at 12 months post PAE. Patients will continue to be followed according to the institutional standard of care follow-up schedule after they complete the study.
Safety will be evaluated throughout the initial 12 months of the study by assessing adverse events and findings on physical examination. Concomitant medication usage will be assessed.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient is aged 50 years or older.
- Patient has signed informed consent
- Patient has experienced lower urinary tract symptoms (LUTS) for at least 6 months prior to study enrollment
- Patient has a prostate size larger than 40g as measured by MRI or CT (if MR not possible)
- Patient has an IPSS score greater than or equal to 13
Patient either:
i. Refuses surgical treatment ii. Is considered high risk for surgical treatment
Patient is either:
i. Refractory to medical treatment ii. Contraindicated for medical treatment
Patient must meet ONE of the following criteria:
- Baseline PSA ≤ 2.5ng/mL
- Baseline PSA > 2.5 ng/mL and ≤ 10 ng/mL AND free PSA ≥ 25% of total PSA (no biopsy required)
- Baseline PSA > 2.5 ng/mL and ≤ 10 ng/mL AND free PSA < 25% of total PSA AND negative prostate biopsy result (minimum of 12 core biopsy) within 12 months
- Baseline PSA >10 ng/mL AND negative prostate biopsy result (minimum of 12 core biopsy) within 12 months
- Patient has a peak urine flow rate < 12ml/sec.
Exclusion Criteria:
- Active prostatitis or urinary tract infection
- History of prostate or bladder cancer, or currently being evaluated for cancer
- Bladder atonia, neurogenic bladder disorder or other neurological disorder that is impacting bladder function.
- Urethral stricture, bladder neck contracture, other potentially confounding bladder pathology, bladder disease, or confounding urethral pathology
- Patient has taken beta blockers, antihistamines, anticonvulsants, or antispasomodics within 1 week of study treatment AND has not been on the same drug dosage for 6 months with a stable voiding pattern.
- Patient has taken antidepressant, anticholinergics, androgens or gonadotropin-releasing hormonal analogues within 2 months of study treatment AND has not been on the same drug dosage for at least 3 months with a stable voiding pattern.
- Patient has taken alpha blockers within 4 weeks of study treatment AND has not been on the same drug dosage for at least 3 months with a stable voiding pattern.
- Patient has taken 5-alpha reductase inhibitors within 3 months of study treatment AND has not been on the same drug for at least 6 months with a stable voiding pattern
- History of open prostate surgery, radiofrequency, or microwave therapy
- Previous open bladder or rectosigmoid colon surgery
- Acute urinary retention requiring an indwelling catheter
- Cystolithiasis within the past 3 months
- Coagulation disturbances not normalized by medical treatment
- Iodinated contrast allergy not controlled with 24-hour steroid preparation
- History of pelvic irradiation
- History of severe peripheral vascular disease or known major iliac arterial occlusive disease
- Interest in future fertility
- Significant cardiac or respiratory disease that the Investigator believes puts the patient at risk for a complication during the procedure
- Acute urinary retention requiring an indwelling catheter
- Life expectancy less than 6 months
- History of rectal disease
- Known immunosuppression either pathological or pharmacological
- Presence of collateral vessel pathways potentially endangering normal anatomy during embolization that cannot be bypassed with the microcatheter
- History of any illness or surgery that might confound the results of the study, by producing symptoms which may be confused with those of the disease process under consideration (e.g., Parkinson's, multiple Sclerosis), or which pose an additional risk to the patient.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Prostate Embolization
Prostate Embolization with acrylic polymer microspheres impregnated with porcine gelatin
|
Embolization of the prostate with acrylic polymer microspheres impregnated with porcine gelatin
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate improvement of symptoms from benign prostatic hyperplasia
Time Frame: 12 months
|
The primary study objective is to evaluate improvement of symptoms from benign prostatic hyperplasia (BPH) as assessed by the International Prostate Symptom Score (IPSS) in a whole number score.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
prostate specific antigen (PSA)
Time Frame: 12 months
|
Change in ng/mL from baseline
|
12 months
|
prostate size
Time Frame: 12 months
|
prostate size measured in grams, as determined by TRUS or MRI
|
12 months
|
peak urine flow rate (Qmax)
Time Frame: 12 months
|
Change from baseline in as measured in ml/sec
|
12 months
|
post-void residual urine volume (PVR)
Time Frame: 12 months
|
ml of urine in the bladder after urination
|
12 months
|
Erectile Function Survey
Time Frame: 12 months
|
as measured in 5. Change from baseline in erectile function as assessed by the International Change from baseline in erectile function as assessed by the International Index of Erectile Function (IIEF) in whole numbers
|
12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Uflacker A, Haskal ZJ, Bilhim T, Patrie J, Huber T, Pisco JM. Meta-Analysis of Prostatic Artery Embolization for Benign Prostatic Hyperplasia. J Vasc Interv Radiol. 2016 Nov;27(11):1686-1697.e8. doi: 10.1016/j.jvir.2016.08.004. Epub 2016 Oct 12.
- Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M. Transurethral Resection of the Prostate (TURP) Versus Original and PErFecTED Prostate Artery Embolization (PAE) Due to Benign Prostatic Hyperplasia (BPH): Preliminary Results of a Single Center, Prospective, Urodynamic-Controlled Analysis. Cardiovasc Intervent Radiol. 2016 Jan;39(1):44-52. doi: 10.1007/s00270-015-1202-4. Epub 2015 Oct 27.
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PAE-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Hyperplasia
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
Assiut UniversityNot yet recruiting
-
NeoTract, Inc.Not yet recruitingBenign Prostatic Hyperplasia
-
Assiut UniversityNot yet recruitingBenign Prostatic Hyperplasia
-
Second Affiliated Hospital, School of Medicine,...RecruitingBenign Prostatic HyperplasiaChina
-
Jewish General HospitalNot yet recruitingBenign Prostatic Hyperplasia
-
Zenflow, Inc.RecruitingBenign Prostatic HyperplasiaAustralia, New Zealand
-
REMD Medical TechnologyRenJi Hospital; Tongji Hospital; Qilu Hospital of Shandong University; Sun Yat-Sen... and other collaboratorsCompletedBenign Prostatic HyperplasiaChina
-
Bioaraba Health Research InstituteCompletedBenign Prostatic HyperplasiaSpain
Clinical Trials on Prostate Embolization
-
Society of Interventional Radiology FoundationNot yet recruitingLower Urinary Tract Symptoms | Benign Prostatic Hyperplasia
-
Group of Research in Minimally Invasive TechniquesUniversidad de Zaragoza; Hospital Clínico Universitario Lozano BlesaWithdrawnBenign Prostatic HyperplasiaSpain
-
Shivank BhatiaMerit Medical Systems, Inc.; Society of Interventional Radiology FoundationTerminatedProstate CancerUnited States
-
Merit Medical Systems, Inc.CompletedLower Urinary Tract Symptoms | Benign Prostatic HyperplasiaUnited States, United Kingdom, Italy, France
-
Antonios LikourezosWithdrawnBenign Prostatic HyperplasiaUnited States
-
Northwestern UniversityCompletedBenign Prostatic Hyperplasia (BPH)United States
-
IMBiotechnologies Ltd.CompletedBenign Prostatic Hyperplasia | Benign Prostatic HypertrophyCanada
-
Saskatchewan Health Authority - Regina AreaCompleted
-
University of Mississippi Medical CenterRecruitingLower Urinary Tract Symptoms | Benign Prostatic Hyperplasia (BPH)United States
-
University of MinnesotaCompletedBenign Prostatic HyperplasiaUnited States